Fiche publication
Date publication
avril 2022
Journal
Clinical and translational gastroenterology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas
,
Dr HABERSETZER François
,
Dr LUPBERGER Joachim
,
Dr MUTTER Catherine
Tous les auteurs :
Saviano A, Habersetzer F, Lupberger J, Simo-Noumbissie P, Schuster C, Doffoël M, Schmidt-Mutter C, Baumert TF
Lien Pubmed
Résumé
Significant hepatocellular carcinoma (HCC) risk persists following chronic hepatitis C (CHC) cure. Preclinical studies have shown that erlotinib, an oral EGFR inhibitor, has antiviral activity and HCC chemopreventive effect. Erlotinib is metabolized in the liver and its safety in patients with CHC is unknown. This study aimed to assess safety and antiviral activity of erlotinib in CHC patients.
Référence
Clin Transl Gastroenterol. 2022 Apr 1;:
